



Community and Mental Health Services

19 October 2021

Studies

A genetic link between risk for Alzheimer's disease and severe COVID-19 outcomes via the OAS1 gene

A study published in Brain has found a link between genetic risk for Alzheimer's disease and susceptibility to critical illness with COVID-19 centred on OAS1, a finding with potential implications for future treatments of Alzheimer's disease and COVID-19, and development of biomarkers to track disease progression.

Anticoagulant prescribing for atrial fibrillation and risk of incident dementia

Incident electronic health record recorded dementia and mild cognitive impairment were less common among patients prescribed direct oral anticoagulants for new atrial fibrillation compared with those prescribed vitamin K antagonists.

<u>Shingles, Zostavax vaccination and risk of developing dementia: a nested</u> case–control study—results from the UK Biobank cohort

This study found that a history of shingles was not associated with an increased risk of dementia. In subjects who were eligible for the immunisation and vaccinated with Zostavax, there was a reduced risk of developing dementia.

<u>Performing arts for dementia carers: feasibility and acceptability of a new multi-modal intervention</u>

Review of a study of a new multi-modal performing arts intervention programme for carers of people with dementia, which suggests this approach is feasible and acceptable.

Cochrane Clinical Answer

What are the benefits and harms of withdrawing cholinesterase inhibitors in people with dementia?

For people with mild to severe dementia, moderate-certainty evidence shows that withdrawing cholinesterase inhibitors probably severely worsens their long-term (≥ 12 months) cognitive function and functional status, with minimal to no important difference in neuropsychiatric status. The evidence for shorter follow-up is similar to that for long-term effects but is more uncertain.